Table 2. Demographics and baseline ocular characteristics of treatment-naive patients.
| BCVA responders | BCVA non-responders | Fundus responders | Fundus non-responders | |
|---|---|---|---|---|
| (57 eyes) | (5 eyes) | (54 eyes) | (8 eyes) | |
| Ratio to naive patients (%) | 91.9 | 8.1 | 87.1 | 12.9 |
| Age, mean ± SD | 68.9 ± 10.2 | 75.8 ± 7.8 | 70.0 ± 10.5 | 66.3 ± 7.6 |
| Male, (eyes [%]) | 39 (68.4) | 2 (40.0) | 37 (68.5) | 4 (50.0) |
| AMD type | ||||
| Typical AMD | 21 | 2 | 21 | 2 |
| PCV | 35 | 2 | 31 | 6 |
| RAP | 1 | 1 | 2 | 0 |
| BCVA, mean ± SD (logMAR) | 0.34 ± 0.41 | 0.30 ± 0.23 | 0.37 ± 0.42 | 0.11 ± 0.23** |
| CRT, mean ± SD (μm) | 364 ± 196 | 283 ± 133 | 355 ± 191 | 371 ± 209 |
| GLD, mean ± SD (μm) | 4185 ± 2608 | 5588 ± 2202 | 4307 ± 2681 | 4236 ± 2011 |
| CCT, mean ± SD (μm) | 204 ± 64 | 200 ± 60 | 203 ± 64 | 212 ± 58 |
| Type 1 CNV (eyes [%]) | 15 (26.3) | 2 (40.0) | 15 (28.8) | 2 (25.0) |
AMD, age-related macular degeneration; PCV, polypoidal choroidal vasculopathy; RAP, retinal angiomatous proliferation; BCVA, best corrected visual acuity; CNV, choroidal neovascularization; CRT, central retinal thickness; GLD, greatest linear dimension; CCT, central choroidal thickness. Two-tailed t-test, **p < 0.01.